Evidence map›Paper›PMID 35385130›Full record

SynthesisJournal of clinical laboratory analysis2022

Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.

Adel Naimi, Ilya Yashmi, Reza Jebeleh, Mohammad Imani Mofrad, Shakiba Azimian Abhar, Yasaman Jannesar, Mohsen Heidary, Reza Pakzad

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Adel NaimiCellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Ilya YashmiStudent Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Reza JebelehStudent Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.ORCID https://orcid.org/0000-0001-7413-8123
Mohammad Imani MofradStudent Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Shakiba Azimian AbharStudent Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Yasaman JannesarStudent Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Mohsen HeidaryCellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.ORCID https://orcid.org/0000-0002-9839-5017
Reza PakzadDepartment of Epidemiology, Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran.
Sabzevar University of Medical Sciences · IRMedical University of Ilam · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies. MATERIAL AND

methodsIn this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the published articles in English from January 1, 2019, until March 10, 2021 were collected and evaluated.

resultsIn total, 53 studies with 2395 patients were included based on inclusion criteria. Most of these studies took place in Spain (14.81%), followed by the USA (11.11%), China (9.26%), and the UK (9.26%). More than half of COVID-19 patients with hematological malignancy were male (56.73%). Oxygen therapy played an important role in COVID-19 treatment. Moreover, anticoagulant therapies such as enoxaparin and heparin were two great assists for these patients. Fever (74.24%), cough (67.64%), and fatigue (53.19%) were the most reported clinical manifestations. In addition, hypertension and dyslipidemia were the most common comorbidities. The mortality rate due to COVID-19 in patients with hematological malignancies was 21.34%.

conclusionThis study demonstrated that hematologic cancer patients were more susceptible to a severe COVID-19 than patients without blood cancer. Thus, the management of COVID-19 in these patients requires much more attention, and their screening should perform regularly.

Indexed as

COVID-19COVID-19 Drug TreatmentHematologic NeoplasmsFemaleHumansMalePandemicsSARS-CoV-2COVID-19leukemialymphomamyelomareview

Identifiers

PMID35385130
PMCPMC9102765
OpenAlexW4224248003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.